CONDITION
Dilated Cardiomyopathy in Dogs
Dilated cardiomyopathy is a condition in which the heart muscle becomes progressively weaker and the main pumping chambers enlarge. As the walls of the heart stretch and thin, the muscle loses its ability to contract forcefully, and blood begins to move less efficiently through the circulation. Over time, this can lead to fluid accumulating in the lungs or abdomen, and to episodes of collapse or sudden death from rhythm disturbances. Owners often arrive at this page because their dog has started coughing, breathing more rapidly at rest, tiring unusually quickly on walks, or has had an episode of weakness or collapse. Some dogs are investigated after a murmur or irregular heartbeat is heard during routine examination, before any outward signs appear. In certain breeds, including Dobermanns, Irish Wolfhounds, and Great Danes, the condition can progress silently for months or years. This page explores what may be observed at different stages, the mechanisms that drive the disease, how it is investigated using imaging and rhythm monitoring, and the medical approaches used to manage fluid overload, support heart function, and address arrhythmias. It does not diagnose an individual animal, but offers a framework for understanding what dilated cardiomyopathy is and how it tends to unfold.
Why this matters now
Dilated cardiomyopathy tends to appear in middle-aged to older dogs, typically between four and ten years of age, though younger animals can occasionally be affected. Certain breeds show a higher incidence, including large and giant breeds such as Dobermann Pinschers, Irish Wolfhounds, and Great Danes, as well as medium-sized breeds such as American Cocker Spaniels, in which a taurine-deficiency-related form of the condition has been described. In some breeds, specific genetic mutations have been identified, while in others the underlying cause remains uncertain. Nutritional factors, particularly taurine or carnitine deficiency, have been associated with the condition in certain breeds and diets, though the relationship is complex and not fully understood.
The condition often develops quietly over months to years, with the heart gradually enlarging and weakening before outward signs become apparent. Some dogs may move from early changes detectable only on imaging to advanced heart failure over weeks to months, while others may remain stable for extended periods. The rate of progression varies considerably between individuals, influenced by factors including breed, the extent of underlying muscle damage, and the presence of rhythm disturbances. Once signs of fluid accumulation or reduced exercise tolerance emerge, the trajectory often accelerates, though the timeframe remains unpredictable for any individual animal. Two features change the picture sharply. Fluid can build up in the lungs over hours to a few days, so a dog that seemed settled one evening may be breathing hard at rest by the next morning. Dangerous ventricular rhythm disturbances can also be present in a dog that looks entirely well, and in Dobermanns in particular a substantial proportion of affected dogs die suddenly, sometimes before any outward sign has appeared. A fainting episode, even a brief one from which the dog recovers fully, can reflect one of these rhythm disturbances. A rising sleeping breathing rate can be counted at home, but it cannot confirm fluid in the lungs, and the heart rhythm cannot be judged by watching the dog at all; these are identified through chest radiographs and an electrocardiogram, with echocardiography assessing the heart itself.
Signals & patterns
Early signals
Reduced stamina during walks
A dog may tire more easily on familiar routes or show less enthusiasm for activities they previously enjoyed. This change can be subtle and gradual, easily mistaken for normal ageing or hot weather.
Faster breathing at rest
The breathing rate when settled or asleep may creep upwards, often noticed by owners who count breaths while the dog sleeps. Healthy dogs at rest or asleep typically take fewer than 30 breaths per minute, and a sleeping rate that stays above this level, or climbs steadily over several days, is one of the earliest recognised markers of fluid beginning to collect in the lungs. This change can appear before any cough or visible breathing effort, so a dog that otherwise looks normal but has a rising sleeping rate is not necessarily stable.
Restlessness at night
A dog may wake more frequently, shift position often, or struggle to settle comfortably. This behaviour can reflect subtle difficulty breathing when lying flat, though many other factors can also cause disturbed sleep.
Later signals
Laboured breathing
Breathing becomes visibly effortful, often rapid and shallow, with the chest and abdomen moving more obviously than usual. The pattern may worsen when lying down, prompting the dog to sit or stand with the elbows held out and the neck extended. Open-mouth breathing at rest, gums that look grey or blue, or pink frothy fluid at the nose or mouth reflect fluid filling the lungs, a state that can progress within hours to the point where the dog cannot take in enough oxygen.
Collapse or weakness
Episodes of sudden weakness or collapse may occur, sometimes lasting only seconds, after which the dog may appear completely normal. These events can reflect rhythm disturbances or insufficient blood flow to the brain and muscles, though other conditions can produce similar patterns. A quick recovery does not mean the cause was minor: in dogs with DCM, fainting is associated with the ventricular arrhythmias that can cause sudden death, and the rhythm responsible is often no longer present by the time the dog is examined, which is why prolonged ECG (Holter) recording is used to look for it.
Abdominal swelling
The abdomen may appear distended or feel firm, reflecting fluid accumulation in the belly cavity. This change tends to develop gradually and may be accompanied by reduced appetite or reluctance to lie down fully.
Coughing
A cough can appear in dogs with DCM, sometimes soft and intermittent and easy to mistake for throat clearing. It is not a reliable early marker: fluid collecting in the lungs usually shows first as a rise in the sleeping breathing rate, and a cough tends to follow that rise rather than come before it. A new cough in a dog with DCM, particularly alongside faster or more effortful breathing, can therefore accompany heart failure that is already developing.
Click to read about the biological mechanisms
How this is usually investigated
Investigation of suspected dilated cardiomyopathy typically begins with a careful history and physical examination, during which subtle changes such as a heart murmur, gallop rhythm, arrhythmia, or muffled heart sounds may be detected. When clinical signs are present or when screening at-risk breeds, the investigation progresses to tests that characterise cardiac structure, function, and rhythm. The combination of investigations used depends on the clinical picture, the breed, and whether the goal is diagnosis of overt disease or detection of occult (preclinical) changes.
Physical examination
Echocardiography
Radiography
24-hour Holter monitoring
N-terminal pro-B-type natriuretic peptide (NT-proBNP)
Options & trade-offs
Management of dilated cardiomyopathy is typically multimodal, combining medications that address the consequences of reduced cardiac output and neurohormonal activation with adjustments to diet and activity. The combination chosen depends on the stage of disease (occult versus overt heart failure), the individual dog's response, and practical considerations for the household. What works well for one dog and owner may be less suitable for another, and approaches often evolve as the condition progresses.
ACE inhibitors and aldosterone antagonists
Angiotensin-converting enzyme (ACE) inhibitors such as enalapril or benazepril, and aldosterone antagonists such as spironolactone, act on the renin-angiotensin-aldosterone system to reduce sodium and water retention, decrease afterload (the resistance the heart pumps against), and mitigate some of the harmful effects of chronic neurohormonal activation on the myocardium. ACE inhibitors are sometimes introduced when systolic dysfunction is identified, before overt heart failure develops, whereas spironolactone is more often added once heart failure has occurred; both are typically continued long-term. Benazepril is authorised in the UK for dogs with congestive heart failure, so starting it before heart failure is off-licence use under the cascade. Enalapril no longer has an authorised veterinary product in the UK, so any use of it in dogs is with a human medicine prescribed under the cascade. Spironolactone is authorised for dogs in the UK, alongside standard therapy, for congestive heart failure caused by degenerative mitral valve disease rather than DCM, so its use in DCM is off-licence use under the cascade.
Trade-offs: These drugs require monitoring of renal function and electrolytes, as they can affect kidney perfusion and potassium balance, particularly when used in combination or in dogs with concurrent renal disease. The benefit in the occult phase is debated for some breeds, and dose adjustments may be needed over time.
Positive inotropes
Pimobendan is a positive inotrope (it increases the strength of myocardial contraction) and vasodilator, widely used in dogs with DCM once echocardiographic evidence of systolic dysfunction is present. In Dobermann Pinschers with preclinical DCM, pimobendan has been shown to delay the onset of overt heart failure and extend survival, and it is commonly used in overt heart failure across breeds to improve cardiac output and clinical signs. Pimobendan is authorised in the UK for dogs with heart failure caused by DCM and for preclinical DCM in Dobermanns; its use before heart failure in other breeds is off-licence use under the cascade.
Trade-offs: Pimobendan is generally well tolerated, though it increases myocardial oxygen demand and may, rarely, be associated with arrhythmias. Its benefit in occult DCM in breeds other than Dobermanns is less well established, and the decision to start treatment in the absence of clinical signs involves weighing potential benefit against cost and the commitment to long-term medication.
Diuretics
Furosemide (frusemide) is the diuretic most commonly used to manage pulmonary oedema and effusions in dogs with congestive heart failure, promoting the elimination of excess fluid and relieving respiratory distress. The dose is adjusted according to the severity of congestion and the dog's response, and in many cases chronic low-dose therapy is continued after the initial crisis is controlled.
Trade-offs: Diuretics can cause dehydration, electrolyte disturbances (particularly low potassium), and prerenal azotaemia, and they require careful dose titration and periodic monitoring of renal function and hydration status. Over-diuresis can reduce cardiac output by decreasing preload excessively, whilst under-treatment leaves the dog uncomfortable and at risk of worsening congestion.
Antiarrhythmic therapy
When ventricular arrhythmias are frequent, complex, or associated with clinical signs such as weakness or collapse, antiarrhythmic drugs may be introduced. Options include sotalol, mexiletine, or amiodarone, chosen based on the characteristics of the arrhythmia and the individual dog's tolerance. None of these is authorised for dogs in the UK; all are human medicines prescribed under the veterinary cascade. The goal is to reduce arrhythmia burden and the risk of sudden death, though complete suppression is often not achievable.
Trade-offs: Antiarrhythmic drugs can themselves be proarrhythmic (capable of worsening or inducing new arrhythmias), and they often require monitoring with repeat Holter studies or electrocardiograms to assess efficacy and detect adverse effects. Response is variable, and in some dogs arrhythmias persist despite treatment.
Dietary modification and taurine or carnitine supplementation
In dogs with DCM, particularly those on grain-free or legume-rich diets or certain breeds with historical associations between diet and DCM (such as American Cocker Spaniels), dietary modification and supplementation with taurine and/or L-carnitine is sometimes pursued. Taurine and L-carnitine are nutritional supplements rather than authorised medicines. The rationale is that deficiencies in these nutrients can contribute to myocardial dysfunction in some cases, and dietary change with or without supplementation may stabilise or, in some dogs, partially reverse cardiac changes if a nutritional component is present.
Trade-offs: The role of diet and supplementation remains unclear in many cases, and response is unpredictable; some dogs show echocardiographic improvement whilst others do not, and it is often impossible to know whether supplementation has altered the disease course. Dietary change can be practically difficult in dogs with established preferences, and the evidence base for supplementation in genetically driven DCM is limited.
Common misconceptions
"A heart murmur is always the first sign of dilated cardiomyopathy."
Many dogs with DCM, particularly in the early (occult) phase, have no murmur at all, and the condition may only be detected through echocardiography or Holter monitoring during screening. Murmurs, when present, typically arise from mitral regurgitation secondary to ventricular dilation rather than being a primary feature of the disease, and some dogs develop overt heart failure without ever having a prominent murmur.
"Dilated cardiomyopathy can be cured if detected early enough."
Genetic and idiopathic DCM is a progressive and irreversible disease; the myocardial damage and fibrosis that characterise the condition cannot be undone. A smaller group of dogs whose DCM is linked to taurine deficiency or diet can show partial improvement after dietary change and supplementation, though full recovery is not assured. In genetic and idiopathic DCM, treatment aims to slow progression, manage the consequences of reduced cardiac function, and improve quality of life, but it does not restore normal cardiac structure or function. Even with treatment, the disease typically advances over time, though the rate of progression varies considerably between individuals.
"All large-breed dogs are equally at risk of dilated cardiomyopathy."
Whilst DCM predominantly affects large and giant breeds, the risk is far from uniform; certain breeds such as Dobermann Pinschers, Great Danes, and Irish Wolfhounds have well-documented genetic predispositions and much higher prevalence than other large breeds. Breed-specific genetic mutations underlie familial DCM, and dogs of non-predisposed breeds, even if large, are at considerably lower baseline risk unless other factors (such as specific dietary exposures) are present.
Related conditions
Hypothyroidism in Dogs
Hypothyroidism in dogs has historically been considered a possible contributor to dilated cardiomyopathy in some cases, though current evidence suggests this link may be less common than once thought. Thyroid hormone influences cardiac muscle metabolism, and severe or prolonged deficiency can occasionally affect heart function.
Pericardial Effusion
A small amount of fluid around the heart can accompany congestive heart failure in DCM, though it rarely compresses the heart. Pericardial effusion from other causes, such as a bleeding right atrial or heart-base tumour, produces weakness, collapse and a swollen abdomen that can look very like advanced DCM in a large-breed dog; the two are told apart by echocardiography, and effusion that compresses the heart can deteriorate over hours.
Obesity in Dogs
Obesity in dogs increases metabolic demand on the cardiovascular system and may influence the progression or clinical expression of dilated cardiomyopathy in affected individuals. Weight management can be part of the broader supportive context when heart function is already compromised.
Congestive Heart Failure in Dogs
DCM is one of the main causes of congestive heart failure in large and giant breed dogs. Failure of the left side of the heart fills the lungs with fluid and produces fast breathing at rest, while failure of the right side can lead to fluid in the abdomen or chest.
Atrial Fibrillation
Atrial fibrillation often develops in giant-breed dogs with DCM, particularly Irish Wolfhounds, and can be detected before other changes. The fast, irregular rhythm reduces the heart's output and frequently coincides with falling exercise tolerance or the onset of heart failure.
Mitral Valve Disease in Dogs
Mitral valve disease is the most common acquired heart disease in dogs and the main alternative explanation for a murmur, cough or faster breathing, particularly in small and medium breeds. In DCM a murmur arises because the enlarged ventricle stretches the valve, whereas in mitral valve disease the valve itself degenerates; echocardiography distinguishes the two.
Arrhythmogenic Right Ventricular Cardiomyopathy (Boxer Cardiomyopathy)
Boxer cardiomyopathy is a separate heart muscle disease that, like DCM in Dobermanns, can cause fainting and sudden death from ventricular arrhythmias, sometimes before any enlargement of the heart is found. A minority of affected Boxers go on to develop an enlarged, weakly contracting heart that resembles DCM.
For owners of predisposed breeds, understanding the rationale and timing of cardiac screening with echocardiography and Holter monitoring can be a useful conversation to have well before any signs appear. European guidelines for Dobermanns describe yearly screening with both tests from three years of age, because a single normal result does not rule out later disease. In dogs with a confirmed diagnosis, many owners count and record the sleeping breathing rate, because a sustained rise is often the first change to appear when fluid starts to return to the lungs, before any cough or visible effort. Laboured breathing at rest, gums that look grey or blue, or a fainting episode mark a different situation from a gradual loss of stamina: they reflect lung fluid or rhythm disturbances that can progress over hours and that cannot be assessed at home. A useful conversation at the time of diagnosis is which specific changes the treating team regards as reasons for the dog to be examined the same day, and how the management plan may evolve as the condition progresses. The interplay between heart and kidney function, and the role of diet and body condition, may also be relevant over the longer term.
Last reviewed: 10 October 2026 · Dr Alastair Greenway MRCVS